BIOMAT Database Logo BIOMAT Database Logo

Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids. 2019

Lejia Sun, and Huayu Yang, and Yilei Mao
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing 100730, China.

UI MeSH Term Description Entries

Related Publications

Lejia Sun, and Huayu Yang, and Yilei Mao
Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
January 2016, Recent patents on anti-cancer drug discovery,
Lejia Sun, and Huayu Yang, and Yilei Mao
Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action.
April 2019, Immunotherapy,
Lejia Sun, and Huayu Yang, and Yilei Mao
Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
January 2016, Cancer journal (Sudbury, Mass.),
Lejia Sun, and Huayu Yang, and Yilei Mao
Hyperprogression of a Sinonasal Squamous Cell Carcinoma Following Programmed Cell Death Protein-1 Checkpoint Blockade.
December 2020, JAMA otolaryngology-- head & neck surgery,
Lejia Sun, and Huayu Yang, and Yilei Mao
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis.
June 2018, Critical care (London, England),
Lejia Sun, and Huayu Yang, and Yilei Mao
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.
January 2017, Cancer journal (Sudbury, Mass.),
Lejia Sun, and Huayu Yang, and Yilei Mao
Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
December 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Lejia Sun, and Huayu Yang, and Yilei Mao
Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade.
August 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Lejia Sun, and Huayu Yang, and Yilei Mao
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1.
October 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Lejia Sun, and Huayu Yang, and Yilei Mao
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors.
December 2021, Expert opinion on biological therapy,
Copied contents to your clipboard!